The combi-targeting concept: Selective targeting of the epidermal growth factor receptor- and Her2-expressing cancer cells by the complex combi-molecule RB24

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 1, 2010, Pages 9-20

  Banerjee, Ranjita ^a   Huang, Ying ^a   McNamee, James P ^b   Todorova, Margarita ^a   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3' BROMOPHENYLAMINO) 6 AMINOQUINAZOLINE; 6 (3 ACETOXYMETHYL 3 METHYL TRIAZENYL) 4 (3' BROMOPHENYLAMINO) QUINAZOLINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; QUINAZOLINE; RB10; RB24; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DNA DAMAGE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BCL-ASSOCIATED DEATH PROTEIN; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COMET ASSAY; DNA DAMAGE; FLOW CYTOMETRY; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSFECTION; TRIAZENES;

EID: 77953759248     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160085     Document Type: Article

References (39)

1. Arteaga CL (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19 (18 Suppl):32S-40S.
2. Banerjee R, Rachid Z, McNamee J, and Jean-Claude BJ (2003) Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. J Med Chem 46:5546-5551.
3. Banerjee R, Rachid Z, Qiu Q, McNamee JP, Tari AM, and Jean-Claude BJ (2004) Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line. Br J Cancer 91:1066-1073.
4. Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, and Jean-Claude BJ (2002) Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for the Combi-Targeting postulates. J Pharmacol Exp Ther 303:238-246.
5. Borg A, Tandon AK, Sigurdsson H, Clark GM, Fernö M, Fuqua SAW, Killander D, and McGuire WL (1990) HER-2/neu amplification predicts poor survival in nodepositive breast cancer. Cancer Res 50:4322-4327.
6. Brahimi F, Rachid Z, Qiu Q, McNamee JP, Li YJ, Tari AM, and Jean-Claude BJ (2004) Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. Int J Cancer 112:484-491.
7. Chambers AF (2009) MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 69:5292-5293.
8. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, and Tortora G (1999) Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5:909-916.
9. Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, et al. (2006) Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 94:1604-1609.
10. Dittmann K, Mayer C, Kehlbach R, Rothmund MC, and Peter Rodemann H. (2009) Radiation-induced lipid peroxidation activates src kinase and triggers nuclear EGFR transport. Radiother Oncol 92:379-382.
11. Domarkas J, Dudouit F, Williams C, Qiyu Q, Banerjee R, Brahimi F, and Jean-Claude BJ (2006) The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem 49:3544-3552.
12. Giocanti N, Hennequin C, Rouillard D, Defrance R, and Favaudon V (2004) Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro. Br J Cancer 91:2026-2033.
13. Huang Y, Sheikh MS, Fornace AJ Jr, and Holbrook NJ (1999) Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Oncogene 18:3431-3439.
14. Khan EM, Heidinger JM, Levy M, Lisanti MP, Ravid T, and Goldkorn T (2006) Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. J Biol Chem 281:14486-14493. (Pubitemid 43848379)
15. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, and Hung MC (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3:802-3808.
16. Lo HW, Hsu SC, and Hung MC (2006) EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 95:211-218.
17. Matheson SL, Brahimi F, and Jean-Claude BJ (2004a) Internalization of the binary EGFR/ DNA-targeting "combi-triazene" SMA41. Biochem Pharmacol 67:1131-1138.
18. Matheson SL, McNamee J, and Jean-Claude BJ (2001) Design of a chimeric 3- methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J Pharmacol Exp Ther 296:832-840. (Pubitemid 32187355)
19. Matheson SL, McNamee JP, and Jean-Claude BJ (2003) Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Cancer Chemother Pharmacol 51:11-20.
20. Matheson SL, McNamee JP, Wang T, Alaoui-Jamali MA, Tari AM, and Jean-Claude BJ (2004b) The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo. J Pharmacol Exp Ther 311:1163-1170.
21. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, et al. (2006) Roles of the RAF/MEK/ ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249-279.
22. McNamee JP, McLean JR, Ferrarotto CL, and Bellier PV (2000) Comet assay: rapid processing of multiple samples. Mutat Res 466:63-69.
23. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, and Arteaga CL (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895. (Pubitemid 34013905)
24. Offterdinger M, Georget V, Girod A, and Bastiaens PI (2004) Imaging phosphorylation dynamics of the epidermal growth factor receptor. J Biol Chem279:36972-36981.
25. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, and Zhou T (2003) Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22:2034-2044.
26. Pegg AE, Dolan ME, and Moschel RC (1995) Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167-223.
27. Qiu Q, Domarkas J, Banerjee R, Merayo N, Brahimi F, McNamee JP, Gibbs BF, and Jean-Claude BJ (2007) The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive. Clin Cancer Res 13:331-340.
28. Qiu Q, Dudouit F, Banerjee R, McNamee JP, and Jean-Claude BJ (2004) Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line. Prostate 59:13-21.
29. Rachid Z, Brahimi F, Katsoulas A, Teoh N, and Jean-Claude BJ (2003) The combitargeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes." J Med Chem 46:4313-4321.
30. Rae JM, Creighton CJ, Meck JM, Haddad BR, and Johnson MD (2007) MDA-MB-435 cells are derived from M14 melanoma cells - a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13-19.
31. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
32. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182.
33. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, and Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
34. Stauffer F, Holzer P, and García-Echeverría C (2005) Blocking the PI3K/PKB pathway in tumor cells. Curr Med Chem Anticancer Agents 5:449-462.
35. Tang CK, Gong XQ, Moscatello DK, Wong AJ, and Lippman ME (2000) Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 60:3081-3087. (Pubitemid 30395838)
36. Todorova M, Larroque A-L, Dauphin-Pierre S, Fang Y-Q, and Jean-Claude BJ (2010) Imaging of the subcellular distribution of a fluorescence-labeled combi-molecule designed to block EGFR tyrosine kinase and damage DNA with a green fluorescent species. Mol Cancer Ther 9:869-882.
37. Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, Morita M, Kakeji Y, and Maehara Y (2006) Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 11:199-208.
38. Trudeau M, Charbonneau F, Gelmon K, Laing K, Latreille J, Mackey J, McLeod D, Pritchard K, Provencher L, and Verma S (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886-898.
39. von Minckwitz G, Jonat W, Fasching P, du Bois A, Kleeberg U, Lück HJ, Kettner E, Hilfrich J, Eiermann W, Torode J, et al. (2005) A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89:165-172.